SPOTLIGHT -
How can clinicians determine the presence of pain in cognitively impaired patients? And how do you know the medication is working if your patient can’t tell you?
Annual Meeting: Poster Investigates the Link Between Semaglutide and Suicidal Ideation
What Will the Future of Alzheimer Disease Treatment Look Like?
The Week in Review: April 22-26
Body Dysmorphic Disorder: Widespread and Potentially Deadly
FDA: Specific Fast Track Designation for Subcutaneous Formulation of Leqembi for Alzheimer Disease Needed for Rolling Review
From the Pages of Psychiatric Times: March 2024